AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05184452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS (20mg/kg, SC)
Description: PGT121.414.LS 20mg/kg administered via SC infusion
Study NCT05184452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS (1.4g, IV)
Description: PGT121.414.LS 1.4g administered via IV infusion
Study NCT05184452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS (1.4g, SC)
Description: PGT121.414.LS 1.4g administered via SC infusion
Study NCT05184452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS (40mg/kg, IV)
Description: PGT121.414.LS 40mg/kg administered via IV infusion
Study NCT06404918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane group
Description: The patients were placed in lateral decubitus position with the operation site up. The probe was placed vertically 3 cm lateral to the T5 spinous process, and the transverse process was identified as an oval hyperechoic sonographic structure. The needle was introduced in an in-plane fashion until the tip lay deep in the erector spinae muscle. 0.5 mL of normal saline was injected to confirm the correct needle tip position by visualizing the spread under the erector spinae muscle. A total of 0.4 mL kg-1 of 0.25% bupivacaine was injected. between the erector spinae muscle and transverse process.
Study NCT06404918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus anterior plane group
Description: Serratus anterior plane block was administered to patient in the supine position with ipsilateral arm abducted to 90°. Under aseptic precautions, linear probe was placed over the midclavicular region in the sagittal plane. Ribs were counted inferiorly and laterally until the fifth rib was identified in midaxillary line. Latissimus dorsi, teres major, and serratus anterior muscles were identified overlying the fifth rib. The intended puncture site was infiltrated with 2 mL of 2% lignocaine, and using ultrasound-guided in-plane approach, the needle was introduced in caudal to cranial direction until the tip was placed between the serratus anterior muscle and external intercostal muscle.
Study NCT05643794 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will receive Placebo during the dosing periods as pre-defined.
Study NCT06145009 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: Limit food intake to 10 hours per day as described in the experimental arm section.
Study NCT05054738 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined Recovery Program
Description: A six-session treatment group designed to explore goals, values, and personal strengths about making a change for overall quality of life, health and well-being combined with skill building designed for helping to live a more stable life in their own home that will include money management for financial success and home maintenance.
Study NCT05054738 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Recovery Program
Description: A six-session treatment group designed to explore goals, values, and personal strengths about making a change for overall quality of life, health and well-being combined with skill building designed for helping to live a more stable life in their own home that will include money management for financial success and home maintenance.
Study NCT05054738 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stable & Able (S&A)
Description: A 90-day Home Telehealth program designed to help maintain skills to stay sober.
Study NCT05817929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 5 ml blood sample will be withdrawn at the surgery start and at the surgery end
Study NCT05632094 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Carnitine
Description: The clozapine-intoxicated patients will receive conventional supportive care in addition to IV L-carnitine with a loading dose of 100 mg/kg IV over 30-60 min (maximum 6 g) and the maintenance dose was 50 mg/kg IV every 8 h.
Study NCT05328830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument assisted soft tissue mobilization
Description: Myofascial release technique will be applied to the Quadriceps, Hamstring and Gastrocnemius muscles of the participant's dominant lower extremity with the Graston technique®. The application will be at 450 angles for each muscle, 2 minutes, for a total of 6 minutes. The IASTM application will include sweep-fan-sweep strokes and cycle through each muscle for the specified time.
Study NCT05328830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foam Roller
Description: Will be applied to the Quadriceps, Hamstring and Gastrocnemius muscles of the participant's dominant lower extremity using rigid Foam Roller. A total of 6 minutes will be applied to a person, 2 minutes for each muscle. Pressure intensity; According to the Visual Analog Scale, which is the point where pain will not be felt but moderate to severe discomfort will be felt, it will be done at a severity of 7/10.
Study NCT05721274 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community mobilization and Conditional community incentives
Description: Non-cash, incentives would be given to clusters which improve the polio vaccine coverage and reduce the refusals and these incentives would be decided with consensus by community and costs would be shared
Study NCT06362135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Home Visit
Description: The virtual home visit will be made through the mobile application developed by the researchers. First, the patients who meet the sampling criteria will be included in the study after the caregivers of the patients apply to the Antalya Health Directorate Antalya Training and Research Hospital Home Health Unit. The virtual home visit is scheduled twice
Study NCT06362135 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Face-to-face home visits will be carried out by the Antalya Education and Research Hospital home health team, as planned.
Study NCT06094881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab Injection [Gazyva]
Description: intravenous Obinutuzumab administration~This study adopts a prospective, single arm, open design method. 60 subjects were enrolled in the study and were treated with CD20 monoclonal antibody (Obinutuzumab: 1000mg) for once.~The first stage is the main research stage (d1-w12), which is the core treatment period. The subjects will receive intravenous infusion of 1000mg Obinutuzumab for once to observe the safety and efficacy during treatment.~The second stage (w12-w48) is the stage of withdrawal from the visit, mainly to observe the safety and continuous efficacy of Obinutuzumab after treatment.
Study NCT05544500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Functional Gum
Description: Functional gum containing a proprietary composition of a herbal extract and vitamins
Study NCT05544500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Basic Chewing Gum
Description: Sugar-free chewing gum
Study NCT04789551 — intervention group
Intervention type: OTHER
Intervention: Blood Sample
Description: a blood sample will be collected
Study NCT06368011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acceptance and commitment therapy
Description: Psychoeducation was delivered in 8 sessions lasting 90 minutes to two separate groups of 8-10 individuals in the experimental group.Group sessions were conducted once a week at the community mental health center under the leadership of the researcher.In total, the psychoeducation lasted 10 weeks, including make-up sessions.
Study NCT06575582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support from Digital Navigators to Treatment Team
Description: The trained professionals (the Digital Navigators) support the treatment teams in the study centers in the selection and integration of suitable apps and digital health applications (DiGAs).
Study NCT06575582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support from Digital Navigators to Patients
Description: The trained professionals (the Digital Navigators) accompany and support the selected patients to find a suitable app for them and integrate it into their treatment.
Study NCT06575582 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training for Digital Navigators
Description: The training takes place in the six study centers and is preferably aimed at medical assistants.
Study NCT05262387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyumjev with 50% basal rate reduction
Description: Administered SC.
Study NCT05262387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog with 50% basal rate reduction
Description: Administered SC.
Study NCT05262387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humalog with 100% basal rate reduction
Description: Administered SC.
Study NCT05262387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyumjev with 100% basal rate reduction
Description: Administered SC.
Study NCT04925063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The starting daily dose of metformin is 500mg once daily, and add a dose of 500mg per week until the target dose of 2000mg once daily if tolerated. Metformin will be continued until disease progression.
Study NCT05016232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP N' Shine: Strength Based Case Management (Stage 1)
Description: Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
Study NCT05016232 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PrEP N' Shine: Stepped Adherence Training and Counseling (Stage 2)
Description: 1. Initially TGW in this arm will receive daily 2-way gender-affirming text message reminders, and~2. Then those continuing to have poor adherence will receive the 4 (once per week for 3 to 4 weeks) more intensive counseling session with a clinical interventionist.
Study NCT06219460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ventilation using two types of face masks
Description: ventilation using two types of face mask
Study NCT06148922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Mental Health First Aid Workshop
Description: a 2-hour workshop delivered by a registered nurse with a MHFA training certificate
Study NCT06148922 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Semi-structured interviews
Description: One-to-one, face-to-face semi-structured interviews will be conducted by a research assistant. The duration would be around 30 minutes.
Study NCT04813796 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1283
Description: Sterile liquid for injection
Study NCT05544500 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar-free tablet
Study NCT04976205 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow (Lymph-node) Irradiation
Description: To the standard procedure for TMI/TMLI target definition, based on simulation WB-CT acquired 10/15 days before BMT, we acquire: WB- magnetic resonance imaging (MRI) the same day of the simulation WB-CT. A verification WB-CT will be performed 3/4 days before the delivery. Plans will be optimized with Volumetric Modulated Arc Therapy (VMAT) technique.
Study NCT04813796 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Sterile liquid for injection
Study NCT04813796 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study NCT06209736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS906 study drug
Description: OMS906 study drug dose 5mg/kg IV administration at 4-week internals
Study NCT05697445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization Techniques
Description: Combination of Cranial and Cervical Mobilization for Cervicogenic headache Patients treatment
Study NCT05697445 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Treatment
Description: Cervicogenic headache exercises
Study NCT05697445 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Cervicogenic headache exercises
Study NCT05011357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Phenylephrine will be administered as an infusion
Study NCT05011357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Control
Description: Saline infusion
Study NCT05469711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PlayPhysio
Description: The gamification will be switched on at day 28 for the participants in arm 1. The trial will run for a further 84 days with the mid-point review half way through this section of the trial.
Study NCT00455039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW572016
Description: Dose: 1500 mg daily
Study NCT05762315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio Storytelling
Description: The audio session is designed to deliver audio narrative developed following the Transformative Storytelling Technique and provide re-structurization of internal caregiver self-stories.
Study NCT05031156 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Splinting of OT Bridge system
Description: splinting of implant abutment using titanium wire followed by pick up using the patient's denture
Study NCT05031156 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Splinting of OT Bridge system
Description: splinting of implant abutment using titanium wire followed by pick up using the patient's denture
Study NCT04765761 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PLMA with introducer
Description: The pro-seal laryngeal mask airway (PLMA) will be inserted along with introducer tool which will be kept in-situ throughout the duration of positive pressure ventilation
Study NCT04765761 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PLMA without introducer
Description: The pro-seal laryngeal mask airway (PLMA) will be inserted along with introducer tool which will be removed after insertion and patient will be ventilated using PLMA without the introducer in-situ throughout the duration of positive pressure ventilation
Study NCT05219448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and self-efficacy coaching
Description: Children and their caregiver(s) in the intervention communities will receive a culturally-adapted, 5-session program consisting of video-based health education and self-efficacy coaching delivered by an indigenous Community Health Worker. Families will be introduced to sugar-free water enhancers that are commercially available and come in the same flavors as regular Tang and Kool-Aid. The sessions will include conversations on related topics, interactive hands-on activities, and homework assignments. Additionally, four brief check-ins will keep families engaged. Local stores in the intervention communities only will carry the sugar-free water enhancers that are highlighted in the health education.
Study NCT05007600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Interactive Courses
Description: In the experimental group, after consensus was reached in the expert meeting (consisting of a doctor specializing in occupational therapy, a doctor specializing in nursing, and a doctor specializing in public health), a 5-days-per-week (Monday to Friday) 8-week intensive online interactive course was designed. The course was made accessible to the participants through a social network app (Line) from 12:00 to 20:30.
Study NCT04859062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine gel 2%
Description: assessing its efficacy in decreasing muscle traction pain,In the operation room, we started inhalational induction of anesthesia with sevoflurane till the patient is deeply anesthetized. In the experimental group, we applied lidocaine gel 2% abundantly below both eyelids of the surgical eye for at least 3 minutes before the surgical incision, while nothing was applied to patients in the control group.
Study NCT04859062 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: In the operation room, we started inhalational induction of anesthesia with sevoflurane till the patient is deeply anesthetized. In control group, we didn't apply lidocaine gel 2% to the operative eye .
Study NCT04886661 — intervention group
Intervention type: OTHER
Intervention: CHRONIC NECK PAIN
Description: Demographic information will be collected. Neck Disability Index will be filled. Physical examination will be performed.
Study NCT05667376 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Local drug delivery
Description: Local application of curcumin gel into the periodontal pocket
Study NCT05667376 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: curcumin gel
Description: curcumin gel
Study NCT04656600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerezyme® / Imiglucerase
Description: Pharmaceutical form: lyophilisate for solution for infusion Route of administration: intravenous
Study NCT04999722 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Traditional mode of management
Description: Traditional model management of Diabetes Mellitus patients
Study NCT04999722 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile APP management
Description: Management of diabetic patients with mobile phone APP
Study NCT05771402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 antibody
Description: Once/two or three weeks, dose lower than the dose used in cancer patients, subcutaneous/intravenous injection
Study NCT05771402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAs
Description: Once/day, 1 capsule/time, oral
Study NCT05771402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAs
Description: Once/day, 1 capsule/time, oral
Study NCT05771402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFNα
Description: Once/week, 180μg/time, subcutaneous injection
Study NCT05771402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-IFNα
Description: Once/week, 180μg/time, subcutaneous injection
Study NCT06481202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Complarate®
Description: The test drug Complarate® was administered as an intravenous infusion at a single dose of 8 mg/kg.
Study NCT06481202 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Actemra®
Description: The reference drug Actemra® was administered as an intravenous infusion at a single dose of 8 mg/kg.
Study NCT05643573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asundexian (BAY2433334)
Description: Once a day
Study NCT05643573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: 5 mg or 2.5 mg, twice a day, according to product label.
Study NCT05643573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asundexian matching placebo
Description: Placebo to asundexian, once a day
Study NCT05643573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban matching placebo
Description: Placebo to apixaban, twice a day
Study NCT05968157 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breast MRI
Description: Supplemental MRI (in addition to standard of care MRI).
Study NCT05968157 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Breast MRI
Description: Supplemental MRI (in addition to standard of care MRI).
Study NCT05968157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIRAI
Description: Artificial intelligence software
Study NCT05965947 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical Nutrition Therapy
Description: One-on-one nutrition assessment, education, and counseling with a Registered Dietitian.
Study NCT06172166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdisciplinary Care for Transition
Description: Young adults with T1D will participate in three visits during which they will see a diabetes nurse educator, psychologist, and transition navigator/social worker who will co-deliver care. TCT Visits 1 and 2 will be before the first adult diabetes healthcare visit, during trial months 1 and 2 respectively. These visits will focus on improving transition readiness, establishing care with an adult T1D specialist, and navigating psychosocial barriers to successful transition. TCT Visit 3 will occur after the first adult T1D healthcare visit, within one month of the first adult T1D care visit or during trial month 7 if the visit has not yet occurred. TCT Visit 3 will focus on overcoming barriers to satisfactory adult T1D healthcare.
Study NCT06560723 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Quality of life test
Description: The results of the various quality-of-life scores used to compile the study statistics (ADL, iADL, MMS, GDS, MNA, EPICES, SPPB, SF-36) will be provided to the doctor, but without any specific comments or recommendations, and then presented to the patient. Number of emergency room visits and hospitalization days, drug untake evalautions and thepareutic compliance (GIRERD score) will be also collected.